11 known cases. View patent page →
Hatch-Waxman ANDA patent infringement action in the District of New Jersey. The multi-patent Xyrem complaint included US 7,668,730 and also asserted the '059, '988, '182, and '963 patents. The case was resolved short of trial and closed.
Antitrust class action in the Xyrem indirect-purchaser litigation. The '730 patent is cited as an Orange Book REMS patent, and the case was consolidated into the In re Xyrem MDL.
Antitrust class action in the Xyrem indirect-purchaser litigation. The '730 patent is cited as an Orange Book REMS patent, and the case was consolidated into the In re Xyrem MDL.
Antitrust class action concerning Xyrem that cited the '730 patent as an Orange Book REMS patent. It was terminated and transferred into the In re Xyrem MDL.
Consolidated antitrust MDL concerning Xyrem. The complaint alleges Jazz patented its REMS processes, and the '730 patent is among the REMS patents identified; no final judgment on the '730 patent's validity or enforceability was confirmed.
Inter partes review petition filed by Par Pharmaceutical against US 7,668,730. The PTAB issued a Final Written Decision.
Inter partes review of US 7,668,730 filed by Wockhardt Bio AG. The proceeding was instituted on Oct. 30, 2015, and reached a Final Written Decision; the latest docket entry noted was July 27, 2016.
Covered Business Method review involving US 7,668,730, filed by Par Pharmaceutical with EUSA Pharma (USA), Inc. listed as assignee. The PTAB did not institute the review on procedural grounds.
Docket number listed as a D.N.J. case involving US 7,668,730; party identities and outcome were not verified in the narrative.
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.